Hair Loss on Ozempic, Wegovy and Mounjaro: Why It Happens and What Recovers

Who This Is For#

This guide is for you if:

• You started semaglutide, tirzepatide or liraglutide for weight or blood sugar and your hair is shedding more than usual
• You are losing weight quickly by any route and want to know whether the hair loss is connected
• You want the rates that were actually reported, not forum anecdotes
• You want to know which blood tests are worth asking for before you buy a supplement
• You are trying to work out whether this needs your prescriber, a dermatologist, or time

This guide is NOT for you if:

• Your hair is coming out in round, smooth, bald patches: read Alopecia Areata
• Your scalp is red, scaly, painful or scarred where the hair has gone: read Scarring Alopecia
• Your thinning is concentrated at the part line and crown and was there before the drug: read Female Pattern Hair Loss: Treatment Options
• Your shedding followed a pregnancy rather than weight loss: read Hair Loss After Pregnancy

How Common Is Hair Loss on GLP-1 Drugs?#

What the Wegovy label reports#

The Wegovy (semaglutide) prescribing information is the only GLP-1 label in our research package that gives percentages for hair loss [1]. The figures come from its weight-management trials, split by dose and by sex.

The gap between women and men is wide at every dose, and the rate climbs with dose. The label does not guess at why; it states that "hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction" [1]. Ozempic is the same molecule under a separate diabetes label that was not part of our review, so these are Wegovy figures, not Ozempic-specific ones.

What the pooled trials show#

Cheng and Chang pooled nine interventional studies (7 RCTs and 2 non-RCTs) with data from 4114 GLP-1 receptor agonist users and found "a significantly higher risk of hair loss in GLP-1 RA users than in placebo users (risk ratio [RR]: 3.252; 95% CI: 1.437 to 7.358)"; "the hair loss event rate following GLP-1 RA therapy was 3.9%" [3]. The wide interval means the size of the excess is not well pinned down. The absolute rate of 3.9% is the more useful number: most people on these drugs do not report hair loss [3].

A systematic review by Gupta and colleagues identified 133 studies, included 24, and found "an increased risk of hair loss with certain GLP-1 RAs, particularly semaglutide and tirzepatide" [4].

Mounjaro and liraglutide: where the numbers run out#

The Mounjaro (tirzepatide) label lists alopecia only under postmarketing experience, as "Skin and Subcutaneous Tissue: alopecia", with no percentage [2]. What the reviews say is qualitative: "Tirzepatide, associated with the greatest magnitude of weight loss, was most frequently linked to telogen effluvium" [4], which fits the weight-loss explanation. Liraglutide (Saxenda, Victoza) appears in the scoping literature [5], but our package contains no verified liraglutide-specific rate, so we do not print one.

Why It Happens: Telogen Effluvium, Not Follicle Damage#

A trigger, not a toxin#

None of the sources we reviewed describes a receptor-level or toxic effect of these drugs on the follicle; every mechanistic account frames the shedding as secondary to weight loss. Burke and colleagues: "hair loss, particularly in the form of telogen effluvium, has been observed, potentially linked to rapid weight loss" [6].

Yorulmaz and colleagues, in a series of 3028 patients, define telogen effluvium as "a common form of non-scarring alopecia, characterized by excessive shedding of telogen club hairs" [8]. A systemic jolt, such as a sudden energy and protein shortfall, pushes an unusually large share of follicles into the resting (telogen) phase together, and they later release their hairs together. The result is diffuse shedding across the whole scalp, a widening part and a thinner ponytail rather than bald spots. Because it is non-scarring, the follicle itself is preserved [8].

The closest analogy is bariatric surgery, a far larger and faster weight-loss stimulus than any injection: "the incidence of hair loss after MBS was 57% (95% CI 42-71%)", more common in younger patients and in women, and correlated with serum zinc, folic acid and ferritin [10]. That is not a GLP-1 figure, but it is a severe version of the same process.

How much, how fast, and why dose matters#

The one study in our package that puts numbers on the trigger is a single-center retrospective series from Kang and colleagues: "TE induced by weight loss occurred at a mean weight loss percentage and mean weight loss rate of approximately 15.21% and 3.54 kg/months" [7]. The study describes telogen effluvium after weight loss generally rather than GLP-1 therapy specifically, and these are averages among people who did develop telogen effluvium, not a safety threshold. The message is consistent: magnitude and pace of loss drive the shedding.

That is also why dose matters. Gupta and colleagues note that "hair loss associated with semaglutide appeared to be dose-dependent, with doses < 2mg weekly rarely implicated while higher obesity-treatment doses were more commonly associated with hair loss" [4]. That is a qualitative synthesis, not a pooled statistic, but it lines up with the Wegovy label's own comparison of 3.3% at 2.4 mg against 5.8% at 7.2 mg [1]. The likely chain is that higher doses produce more weight loss, and more weight loss produces more telogen effluvium; that chain is inferred from these sources, not measured by them.

When It Starts and What Recovers#

Timing#

None of our sources gives a verified interval between starting the drug and the start of shedding, so we do not print one. Qualitatively, telogen effluvium lags its trigger: follicles shift into rest and complete that rest before the hair drops, so shedding follows the weight loss rather than the first injection.

Measure rather than worry: photograph your part line and hairline under the same light each month, and use the shedding check to gauge whether what you see exceeds normal daily loss. Tracking Progress with Photos gives a method.

What recovers, and what the evidence does not tell you#

Because telogen effluvium is non-scarring [8], the follicles that shed are still there and still capable of producing hair. That is the most reassuring fact in this guide. What our package does not support is a recovery timeline: standard teaching is that telogen effluvium settles once its trigger settles, but we could not verify a "regrowth by month X" claim against a quotable source, so we are not printing one. The trigger settling means weight stabilizing and energy and protein intake adequate for your new weight, both things to work on with the prescriber.

Two complications matter. The scoping reviews also contain reports of pattern hair loss in people on these drugs [5]; a telogen shed can unmask female pattern hair loss that was already there, and that component does not resolve on its own. If shedding slows but the part keeps widening, read Diffuse Thinning vs Pattern Baldness. And if a nutritional deficit is now part of the picture, the shed can persist until it is corrected.

Nutritional Checks Worth Asking For#

Ferritin and iron#

Ferritin has the strongest real-world claim to relevance. In the Yorulmaz series of 3028 telogen effluvium patients, serum ferritin was the most frequently ordered test, and "iron replacement therapy represented the most common treatment at 37.5% of prescriptions" [8]. In a case-control study of women with telogen effluvium and healthy controls, ferritin was lower in the telogen effluvium group (P < 0.05), and the authors conclude that "iron deficiency anemia is thought of as a factor in female patients with telogen effluvium" [9]. This matters most for women, in whom the Wegovy label reports hair loss at several times the rate seen in men [1], and low ferritin is a recognised factor in women with telogen effluvium [9]. See Ferritin and Hair Loss and Iron Deficiency Hair Loss in Women.

Vitamin D, B12, zinc and folate#

The same series found that "vitamin D deficiency appeared in 72.2% of screened individuals, with B12 deficiency at 30.7%" [8]. Those are prevalence figures among people already being worked up for telogen effluvium, not proof of causation, but high enough that checking is reasonable. Zinc and folic acid join ferritin as the markers correlated with post-bariatric hair loss [10], and a review of post-bariatric micronutrient deficiency lists hair loss among its manifestations and recommends periodic monitoring with individualized supplementation rather than guesswork [11].

Thyroid function belongs in any hair-loss workup; see Thyroid Hair Loss. For the full request list, see Women's Hair Loss Blood Tests or run the blood test tool.

Protein and total intake#

This check does not come on a lab form. Our package contains no study quantifying protein intake in GLP-1 users with hair loss, so the evidence is thin and we do not print a target. These drugs reduce appetite, and a reduced appetite does not automatically protect protein; if meals have shrunk to a few bites, ask the prescriber or a dietitian to look at what is actually being eaten. See Protein Intake for Hair.

When to See a Clinician#

Prescriber first, dermatologist for red flags#

The prescriber is the first stop: they know the dose and titration schedule, can see how fast the weight is coming off, and can order the blood work above in a single visit. Bring photographs and a plain account of what you eat in a day. The conversation is about pace, intake and testing, not about whether to quit.

A dermatologist is the right next step if the pattern does not fit a diffuse shed. Go promptly if you notice:

• Hair coming out in defined round or oval patches with smooth skin underneath
• Redness, scale, pustules, pain, burning or itching where hair is lost
• Skin that looks shiny, or follicle openings that have disappeared
• Loss of eyebrow or body hair alongside scalp hair
• Fatigue, fever, joint pain, or weight loss beyond what the drug was expected to produce
• Shedding that keeps worsening well after weight has stabilized

Those features point away from telogen effluvium and toward conditions that need a diagnosis, some urgently. See When to See a Dermatologist.

What Not to Do#

The mistakes that cost people the most#

Do not stop or change the drug on your own. This is general clinical guidance rather than something our sources tested, but it is the point most worth making. These medicines are prescribed for weight, blood sugar and cardiometabolic reasons that do not go away because hair is shedding. If the shedding is intolerable, say so to your prescriber; a slower titration or a plan for intake is their call, not a decision to make alone.

Do not supplement blind. Iron, zinc and vitamin D are worth testing, and none should be taken at high doses without a result showing you need them. See Iron Supplements and Zinc and Hair Loss.

Do not treat a shed as pattern loss, or pattern loss as a shed. Starting minoxidil for a self-limiting telogen effluvium commits you to an indefinite treatment you may not have needed; waiting out female pattern hair loss loses ground you will not get back.

Do not cut intake further to speed things up. A restrictive diet on top of an appetite-suppressing drug deepens the deficit that caused the shed.

Do not read the label numbers as your odds. A 3.3% rate at 2.4 mg [1] describes a trial population; your own risk depends on how much you lose, how fast, what you eat, and what your ferritin was before you started.

Hair loss, even temporary hair loss, is distressing, and that is not vanity. If it is affecting how you feel about yourself, Emotional Impact of Hair Loss is written for exactly this.

Frequently Asked Questions#

Related Resources#

• Telogen Effluvium
• Ferritin and Hair Loss
• Women's Hair Loss Blood Tests
• Protein Intake for Hair
• Vitamin D and Hair Loss
• Diffuse Thinning vs Pattern Baldness
• When to See a Dermatologist
• Women's Hair Loss: The Complete Guide